A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation
- 17 September 1999
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 44 (5), 372-380
- https://doi.org/10.1007/s002800050992